Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. Our approach addresses the central problem of cancer research: tumor-targeted killing. We focus on targets either lost or gained in cancer cells, potentially creating breakthrough therapies to treat most cancers. The company was founded in 2018 by Alexander K...
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. Our approach addresses the central problem of cancer research: tumor-targeted killing. We focus on targets either lost or gained in cancer cells, potentially creating breakthrough therapies to treat most cancers. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and raised a Series A financing of $57 million. We are currently advancing a pipeline of programs towards the clinic.

List your booth number for exhibitions, ask us